The Evanthea Dementia Reversal clinical trial has officially concluded and the results are extraordinary. According to Dr. Dale Bredesen, preliminary findings show positive results that surpass anything previously published in the field of Alzheimer’s disease, dementia and cognitive health. These outcomes represent a major step forward in how we understand, treat, and reverse memory loss in its earliest stages.
Kemper Cognitive Wellness was honored to be selected as one of only six clinical sites in the United States to conduct the Evanthea Dementia Reversal Trial. This distinction reflects Kemper’s leadership and commitment to brain health, precision medicine, and innovative approaches in cognitive care. Lead by Dr. Nate Bergman and our team of brain health experts, Kemper Cognitive Wellness evaluated the effects of various precision medicine and lifestyle-based interventions designed to reverse memory loss in individuals with mild cognitive impairment (MCI) and early dementia.
This is the first clinical trial of its kind to systematically identify and treat contributors to cognitive decline, including, but certainly not limited to:
- Toxin exposure such as mold and other environmental toxins linked to cognitive decline;
- Metabolic and biochemical imbalances that affect brain energy and cognitive function;
- Microbiome imbalances driving inflammation as well as issues with memory and processing speed;
- Epigenetics or gene expression and patterns affecting biological aging markers.
These factors are rarely evaluated by conventional medicine today. When the root cause was identified and actively treated as part of the trial protocol, cognitive function and overall health significantly improved. The early data is already providing powerful insights and improvements to memory, executive function, processing speed and overall cognition and health.
